Kunisaburo Moridera

Is growth hormone associated with diabetic retinopathy

The role of growth hormone (GH) in the pathogenesis of diabetic retinopathy was evaluated in 150 patients with non-insulin-dependent diabetes mellitus by measuring urinary GH excretion using a highly sensitive enzyme immunoassay. Urinary GH excretion was not significantly different among diabetic patients without retinopathy (mean, 2.4 ng/day; range, < 0.3-20.0 ng/day), with background retinopathy (2.7 ng/day; < 0.3-22.0 ng/day), and with proliferative retinopathy (3.1 ng/day, 0.9-15.6 ng/day). These data suggest that GH does not play a role for the pathogenesis of diabetic retinopathy through the increased physiological secretion.

Growth hormone binding protein in Werner's syndrome

objective GH and growth hormone binding protein in Werners syndrome were investigated to elucidate their relation to the short stature

A Normal Ovulatory Woman With Hyperprolactinemia: Presence of Anti-Prolactin Antibody and the Regulation of Prolactin Secretion

We present the case of a normal ovulatory woman with marked hyperprolactinemia and no evidence of a pituitary adenoma on CT and MRI. Gel filtration studies showed that most immunoreactive PRL was eluted as 150K-170K macroprolactin. Anti-PRL autoantibody was detected and Scatchard analysis revealed a low-affinity (the association constant: 1.29 x 10(7) l/mol), high-capacity (the maximal binding capacity: 1174 micrograms/l) antibody. Dopamine had little suppressive effect on PRL levels and an antidopaminergic agent elicited an augmented response of PRL secretion. These results suggest that the presence of anti-PRL autoantibody may delay the clearance of PRL and/or may alter the central regulation of PRL secretion.